Quantcast
Last updated on April 17, 2014 at 7:54 EDT

Latest EpiVax Inc. Stories

2013-12-03 08:31:26

Full article: http://bit.ly/EpiVax_Biotest DREIEICH, Germany and PROVIDENCE, R.I., Dec. 3, 2013 /PRNewswire/ -- Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII (FVIII) should be developed. The coagulation factor VIII used for Hemophilia therapy will be altered in such a way that the immune system of the patients may not respond by...

2013-04-24 08:30:13

PROVIDENCE, R.I. and SAN DIEGO, April 24, 2013 /PRNewswire/ -- Full article - http://bit.ly/EpiAtla13 EpiVax Inc., an unique immunology company with a strong focus on immunogenicity mitigation and BioAtla, LLC, a San Diego headquartered antibody therapeutics developer, today announced a collaborative agreement to incorporate EpiVax's proprietary immunogenicity screening technology into BioAtla's antibody Express Humanization(TM) platform. (Logo:...

2013-04-13 08:20:19

PROVIDENCE, R.I., April 13, 2013 /PRNewswire/ -- Full Story - http://bit.ly/H7N9EpiVax The H7N9 emerging from China is a stealth virus. State of the art bioinforamatics tools have enabled EpiVax to predict that it will be hard to make vaccines and diagnostics for the new H7N9 flu virus (also called H7N9A/Shanghai/1/2013). H7N9 has fewer T cell epitopes than most previously circulating strains of flu, meaning that it may be able to fly under the immune system's radar. Making a rapid...

2013-02-12 08:31:37

PROVIDENCE, R.I., Feb. 12, 2013 /PRNewswire/ -- EpiVax, Inc. is pleased to announce a new Collaborative Research Agreement with Novozymes Biopharma. The collaboration will enable EpiVax to rapidly advance its Tregitope immune-modulating technology as a potential treatment for autoimmune diseases. When used as a buffering agent, albumin has excellent safety and pharmacokinetic profiles. Fusing Tregitopes to Novozymes' proven albumin-based half-life extension platform will create a safe and...

2012-11-16 16:23:45

PROVIDENCE, R.I., Nov. 16, 2012 /PRNewswire/ -- Full Article Here (Logo: http://photos.prnewswire.com/prnh/20121116/NE15175LOGO ) Providence-based biotech company EpiVax, Inc. was awarded a new $55,000 grant from the GBS-CIDP Foundation International, to explore using Tregitopes as a novel immuno-modulator therapy for a nerve disease that is currently treated with intravenous immunoglobulin G (IVIG). This award and the recent addition of an SBIR grant for $600,000 to explore the use of...

2011-02-02 15:42:08

HelicoVax vaccine targets H. pylori     * When delivered intranasally, vaccine was found to be more effective    * Funding will support future clinical trials to test effectiveness in humans A new study led by researchers at Rhode Island Hospital in collaboration with the University of Rhode Island (URI) and EpiVax. Inc, a privately owned vaccine development company in Providence, RI, has identified a potential vaccine capable of reducing colonization of...

2008-10-27 12:00:10

PROVIDENCE, R.I., Oct. 27 /PRNewswire/ -- Dr. Annie De Groot, CEO of EpiVax, is the lead author on an article highlighting key findings about the activation of natural regulatory T cells by IgG Fc-derived peptide, also known as Epi-13 or "Tregitopes." These findings were published in the October 8 issue of the prestigious Blood, the medical journal published by the American Society of Hematology. In an accompanying editorial, Rachel Caspi of the National Institutes of Health (NIH) wrote,...

2008-07-08 09:00:12

EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH), to develop "Epi-13", a novel therapeutic for the prevention and treatment of Type 1 diabetes, a devastating and chronic autoimmune disease that affects three million Americans. NIDDK will provide EpiVax $600,000 over two years to reach...